Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
Co-Diagnostics Inc. (CODX), a molecular diagnostics developer focused on infectious disease and precision testing solutions, is trading at $1.39 as of 2026-04-13, marking a 1.09% gain in the latest trading session. This analysis outlines key market context, technical levels, and potential price scenarios for the stock in the near term, with no recent earnings data available for the company as of this writing. While CODX has traded in a relatively tight range in recent weeks, shifts in sector sen
Is Co-Diag (CODX) Stock Undervalued Now | Price at $1.39, Up 1.09% - Undervalued Stocks
CODX - Stock Analysis
4475 Comments
1505 Likes
1
Emika
Senior Contributor
2 hours ago
If only I checked one more time earlier today.
👍 20
Reply
2
Nichoas
Legendary User
5 hours ago
That’s some next-gen thinking. 🖥️
👍 22
Reply
3
Shanequia
Loyal User
1 day ago
Real-time US stock currency and international exposure analysis for understanding global business impacts. We help you understand how exchange rates and international operations affect your portfolio companies.
👍 137
Reply
4
Chardae
Influential Reader
1 day ago
Timing just wasn’t on my side this time.
👍 194
Reply
5
Adahir
Elite Member
2 days ago
Early trading suggests a bullish bias, but watch afternoon sessions closely.
👍 145
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.